Cargando…
Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia
BACKGROUND: The mechanism of action of imatinib is known to involve the Fas-mediated apoptosis pathway. Consequently inter-individual variations in this apoptosis pathway might be associated with imatinib response or resistance. METHODS: This study attempted to focus on eight genotypes in the apopto...
Autores principales: | Zheng, Qiaoli, Cao, Jiang, Hamad, Nada, Kim, Hyeoung-Joon, Moon, Joon Ho, Sohn, Sang Kyun, Jung, Chul Won, Lipton, Jeffrey H., Kim, Dennis Dong Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806489/ https://www.ncbi.nlm.nih.gov/pubmed/27009330 http://dx.doi.org/10.1186/s12967-016-0837-5 |
Ejemplares similares
-
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia
por: Park, Jong-Ho, et al.
Publicado: (2018) -
OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014) -
Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia
por: Ahn, Seo-Yeon, et al.
Publicado: (2023) -
Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018) -
FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
por: Ahn, Jae-Sook, et al.
Publicado: (2022)